252 related articles for article (PubMed ID: 19880522)
1. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.
Lim ST; Miller NL; Nam JO; Chen XL; Lim Y; Schlaepfer DD
J Biol Chem; 2010 Jan; 285(3):1743-53. PubMed ID: 19880522
[TBL] [Abstract][Full Text] [Related]
2. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.
Lim ST; Chen XL; Lim Y; Hanson DA; Vo TT; Howerton K; Larocque N; Fisher SJ; Schlaepfer DD; Ilic D
Mol Cell; 2008 Jan; 29(1):9-22. PubMed ID: 18206965
[TBL] [Abstract][Full Text] [Related]
3. The Pyk2 FERM regulates Pyk2 complex formation and phosphorylation.
Riggs D; Yang Z; Kloss J; Loftus JC
Cell Signal; 2011 Jan; 23(1):288-96. PubMed ID: 20849950
[TBL] [Abstract][Full Text] [Related]
4. Conformational Dynamics of FERM-Mediated Autoinhibition in Pyk2 Tyrosine Kinase.
Loving HS; Underbakke ES
Biochemistry; 2019 Sep; 58(36):3767-3776. PubMed ID: 31403288
[TBL] [Abstract][Full Text] [Related]
5. Protein-tyrosine kinase CAKbeta/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 alpha2 helix and thus forming its dimer.
Kohno T; Matsuda E; Sasaki H; Sasaki T
Biochem J; 2008 Mar; 410(3):513-23. PubMed ID: 18031286
[TBL] [Abstract][Full Text] [Related]
6. FERM control of FAK function: implications for cancer therapy.
Lim ST; Mikolon D; Stupack DG; Schlaepfer DD
Cell Cycle; 2008 Aug; 7(15):2306-14. PubMed ID: 18677107
[TBL] [Abstract][Full Text] [Related]
7. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
[TBL] [Abstract][Full Text] [Related]
8. FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.
Graham K; Moran-Jones K; Sansom OJ; Brunton VG; Frame MC
PLoS One; 2011; 6(12):e27806. PubMed ID: 22194793
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines.
Zhang Z; Knoepp SM; Ku H; Sansbury HM; Xie Y; Chahal MS; Tomlinson S; Meier KE
Clin Exp Metastasis; 2011 Aug; 28(6):551-65. PubMed ID: 21533871
[TBL] [Abstract][Full Text] [Related]
10. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
Zhong B; Shingyoji M; Hanazono M; Nguyễn TT; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
Apoptosis; 2020 Aug; 25(7-8):535-547. PubMed ID: 32468177
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.
Ou WB; Lu M; Eilers G; Li H; Ding J; Meng X; Wu Y; He Q; Sheng Q; Zhou HM; Fletcher JA
Br J Cancer; 2016 Nov; 115(10):1253-1263. PubMed ID: 27736841
[TBL] [Abstract][Full Text] [Related]
12. B cell receptor-induced phosphorylation of Pyk2 and focal adhesion kinase involves integrins and the Rap GTPases and is required for B cell spreading.
Tse KW; Dang-Lawson M; Lee RL; Vong D; Bulic A; Buckbinder L; Gold MR
J Biol Chem; 2009 Aug; 284(34):22865-77. PubMed ID: 19561089
[TBL] [Abstract][Full Text] [Related]
13. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
14. The Pyk2 FERM domain as a target to inhibit glioma migration.
Loftus JC; Yang Z; Tran NL; Kloss J; Viso C; Berens ME; Lipinski CA
Mol Cancer Ther; 2009 Jun; 8(6):1505-14. PubMed ID: 19509258
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Guessous F; Yang Y; Johnson E; Marcinkiewicz L; Smith M; Zhang Y; Kofman A; Schiff D; Christensen J; Abounader R
Mol Cancer Ther; 2012 Feb; 11(2):288-97. PubMed ID: 22188814
[TBL] [Abstract][Full Text] [Related]
17. Critical role of the FERM domain in Pyk2 stimulated glioma cell migration.
Lipinski CA; Tran NL; Dooley A; Pang YP; Rohl C; Kloss J; Yang Z; McDonough W; Craig D; Berens ME; Loftus JC
Biochem Biophys Res Commun; 2006 Oct; 349(3):939-47. PubMed ID: 16962067
[TBL] [Abstract][Full Text] [Related]
18. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.
Murphy JM; Jeong K; Ahn EE; Lim SS
J Biol Chem; 2022 Jun; 298(6):102013. PubMed ID: 35525274
[TBL] [Abstract][Full Text] [Related]
19. Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts.
Lipinski CA; Tran NL; Viso C; Kloss J; Yang Z; Berens ME; Loftus JC
J Neurooncol; 2008 Nov; 90(2):181-9. PubMed ID: 18648907
[TBL] [Abstract][Full Text] [Related]
20. Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival.
Sadagopan S; Veettil MV; Chakraborty S; Sharma-Walia N; Paudel N; Bottero V; Chandran B
Oncogene; 2012 Nov; 31(46):4835-47. PubMed ID: 22266868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
